PC945 is the only potent, novel triazole anti-fungal that has been specifically developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, retention in lung tissues that offers a long duration of action and minimal systemic exposure.
PC945 is 30- to 100-fold more potent than voriconazole against Aspergillus fumigatus and exhibits minimal systemic bioavailability after inhaled administration and is intended for delivery by a standard, off-the-shelf nebulizer.
A phase 1 clinical trial of PC945 was completed in 2018.
PC945 has been used on a “special needs” basis in patients who have not responded to multiple standard-of-care (SOC) antifungal therapies, with extraordinary results. As of July 2020, of the nine (9) patients treated, positive clinical results were observed in eight (8) patients.
A Phase 3 study of PC945 for adults, who have limited or no alternative treatment options, for the treatment of invasive pulmonary aspergillus disease as part of a combined antifungal regimen will be initiated in 2021.
